Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity. Mavacamten, an allosteric inhibitor, has shown significant im...

Descripción completa

Detalles Bibliográficos
Autores principales: Rangwala, Hussain Sohail, Fatima, Hareer, Ali, Mirha, Ahmed, Syed Taha, Rangwala, Burhanuddin Sohail, Abbas, Syed Raza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693538/
https://www.ncbi.nlm.nih.gov/pubmed/38041770
http://dx.doi.org/10.1186/s43044-023-00427-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693538/
https://www.ncbi.nlm.nih.gov/pubmed/38041770
http://dx.doi.org/10.1186/s43044-023-00427-5

Ejemplares similares